{
    "root": "3531b9e4-c26d-e9a3-e063-6394a90a2c48",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pioglitazole and metformin hydrochloride",
    "value": "20250515",
    "ingredients": [
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "PIOGLITAZONE HYDROCHLORIDE",
            "code": "JQT35NPK6C",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8229"
        },
        {
            "name": "METFORMIN HYDROCHLORIDE",
            "code": "786Z46389E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6802"
        }
    ],
    "indications": {
        "text": "pioglitazone metformin hydrochloride tablets indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus limitations pioglitazone metformin hydrochloride tablets recommended treat type 1 diabetes mellitus diabetic ketoacidosis .",
        "doid_entities": [
            {
                "text": "type 2 diabetes mellitus (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            },
            {
                "text": "type 1 diabetes mellitus (DOID:9744)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9744"
            },
            {
                "text": "diabetic ketoacidosis (DOID:1837)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1837"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 obtain liver tests initiation . abnormal , caution treating pioglitazone metformin hydrochloride , investigate probable cause , treat ( possible ) , follow appropriately . ( 2.1 ) \u2022 take orally meals reduce gastrointestinal metformin ( 2.1 ) \u2022 individualize starting dose based patient \u2019 current regimen titrate gradually , needed assessing therapeutic response tolerability . maximum recommended total daily pioglitazone 45 mg metformin 2,550 mg. ( 2.2 ) \u2022 recommended starting patients nyha class class ii congestive heart failure 15 mg pioglitazone 850 mg metformin hcl orally daily . ( 2.4 ) \u2022 prior initiation , assess renal function estimated glomerular filtration rate ( egfr ) . ( 2.2 ) contraindicated patients egfr 30 ml/min initiation recommended patients egfr 30 45 ml/min assess risk/benefit continuing pioglitazone metformin hydrochloride egfr falls 45 ml/min discontinue egfr falls 30 ml/min \u2022 monitor patients events related fluid retention initiation dose increases . ( 2.4 ) \u2022 pioglitazone metformin hydrochloride may need discontinued time , prior , iodinated contrast imaging procedures . ( 2.6 )",
        "doid_entities": [
            {
                "text": "congestive heart failure (DOID:6000)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6000"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "pioglitazone metformin hydrochloride tablets , usp 15 mg / 500 mg : white off-white coloured , capsule shaped , film-coated tablets debossed 'c27 ' one side plain side . ndc : 72162-2497-2 : 180 tablets bottle ndc : 72162-2497-6 : 60 tablets bottle storage : store 20\u00ba 25\u00ba c ( 68\u00ba 77\u00ba f ) ; excursions permitted 15\u00ba 30\u00ba c ( 59\u00ba 86\u00ba f ) [ usp controlled room temperature ] . keep container tightly closed , protect moisture humidity repackaged/relabeled : bryant ranch prepack , inc. burbank , ca 91504",
    "adverseReactions": "pioglitazone metformin hydrochloride tablets contraindicated patients : \u2022 established nyha class iii iv heart failure time pioglitazone metformin hydrochloride tablets initiation [ boxed warning ] . \u2022 severe renal impairment ( egfr 30 ml/min ) [ ( 5.2 ) ] . \u2022 history serious hypersensitivity pioglitazone , metformin hcl , excipients pioglitazone metformin hydrochloride tablets . \u2022 acute chronic metabolic acidosis , including diabetic ketoacidosis [ ( 5.2 ) ] .",
    "indications_original": "Pioglitazone and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus\n                  \n                     Limitations of Use\n                  \n                  Pioglitazone and metformin hydrochloride tablets is not recommended to treat type 1 diabetes mellitus or diabetic ketoacidosis.",
    "contraindications_original": "\u2022 Obtain liver tests before initiation. If abnormal, use caution when treating with pioglitazone and metformin hydrochloride, investigate the probable cause, treat (if possible), and follow appropriately. ( 2.1 ) \u2022 Take orally with meals to reduce gastrointestinal adverse reactions with metformin ( 2.1 ) \u2022 Individualize the starting dose based on the patient\u2019s current regimen and titrate the dosage gradually, as needed after assessing therapeutic response and tolerability. The maximum recommended total daily dosage is pioglitazone 45 mg and metformin 2,550 mg. ( 2.2 ) \u2022 Recommended starting dosage in patients with NYHA Class I or Class II congestive heart failure is 15 mg of pioglitazone and 850 mg of metformin HCl orally once daily. ( 2.4 ) \u2022\u00a0Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR). ( 2.2 ) o\u00a0Contraindicated in patients with eGFR below 30 mL/min o\u00a0Initiation is not recommended in patients with eGFR between 30 to 45 mL/min o\u00a0Assess risk/benefit of continuing pioglitazone and metformin hydrochloride if eGFR falls below 45 mL/min o\u00a0Discontinue if eGFR falls below 30 mL/min \u2022\u00a0Monitor patients for adverse events related to fluid retention after initiation and dose increases. ( 2.4 ) \u2022\u00a0Pioglitazone and metformin hydrochloride may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures. (2.6)",
    "warningsAndPrecautions_original": "Pioglitazone and metformin hydrochloride tablets, USP 15 mg / 500 mg: White to off-white coloured, capsule shaped, film-coated tablets debossed with 'C27' on one side and plain on the other side.\n                  \n                  NDC: 72162-2497-2: 180 Tablets in a BOTTLE\n                  NDC: 72162-2497-6: 60 Tablets in a BOTTLE\n                  \n                  Storage: Store at 20\u00ba to 25\u00ba C (68\u00ba to 77\u00ba F); excursions permitted to 15\u00ba to 30\u00ba C (59\u00ba to 86\u00ba F) [see USP Controlled Room Temperature]. Keep container tightly closed, and protect from moisture and humidity\n                  \n                  Repackaged/Relabeled by:\n  \nBryant Ranch Prepack, Inc.\n  \nBurbank, CA 91504",
    "adverseReactions_original": "Pioglitazone and metformin hydrochloride tablets are contraindicated in patients with:\n                  \u2022\u00a0Established NYHA Class III or IV heart failure at the time of pioglitazone and metformin hydrochloride tablets initiation\n \n  [see Boxed Warning].\n                       \u2022\u00a0Severe renal impairment (eGFR below 30 mL/min)\n \n  [see Warnings and Precautions (5.2)].\n                       \u2022\u00a0A history of serious hypersensitivity to pioglitazone, metformin HCl, or any of the excipients in pioglitazone and metformin hydrochloride tablets. \n    \u2022\u00a0Acute or chronic metabolic acidosis, including diabetic ketoacidosis\n \n  [see Warnings and Precautions (5.2)].",
    "drug": [
        {
            "name": "Pioglitazole and metformin hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6801"
        }
    ]
}